Ligand acquires life cycle management technology company CyDex
This article was originally published in Scrip
Ligand Pharmaceuticals is forking out $31.2 million up front to acquire CyDex Pharmaceuticals to accelerate its financial growth, expand the portfolio, and provide a drug reformulation platform.
You may also be interested in...
Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.